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The immune cell infiltrate populating
meningiomas is composed of mature,
antigen-experienced T and B cells
Liangjuan Fang, Daniel E. Lowther, Matthew L. Meizlish, Richard C. E. Anderson,
Jeffrey N. Bruce, Lesley Devine, Anita J. Huttner, Steven H. Kleinstein, Jae-Yun Lee,
Joel N. H. Stern, Gur Yaari, Laura Lovato, Katharine M. Cronk, and Kevin C. O’Connor
Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (L.F.);
Department of Neurology, Yale School of Medicine, New Haven, Connecticut (L.F., M.L.M., L.L., J.-Y.L., J.N.H.S.,
D.E.L., K.C.O.); Human and Translational Immunology Program, Yale School of Medicine, The Anlyan Center for
Medical Research & Education, New Haven, Connecticut (K.C.O.); Department of Neurosurgery, The
Neurological Institute, Columbia University College of Physicians and Surgeons, New York, New York (R.C.E.A.,
J.N.B.); Department of Pathology, Yale School of Medicine, New Haven, Connecticut (A.J.H., G.Y., S.H.K.);
Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut (L.D.); Interdepartmental
Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut (S.H.K.);
Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center,
Phoenix, Arizona (K.M.C.)

Background. Meningiomas often harbor an immune cell
infiltrate that can include substantial numbers of T and B
cells. However, their phenotype and characteristics
remain undefined. To gain a deeper understanding of
the T and B cell repertoire in this tumor, we characterized
the immune infiltrate of 28 resected meningiomas representing all grades.
Methods. Immunohistochemistry was used to grossly
characterize and enumerate infiltrating lymphocytes. A
molecular analysis of the immunoglobulin variable
region of tumor-infiltrating B cells was used to characterize their antigen experience. Flow cytometry of fresh
tissue homogenate and paired peripheral blood lymphocytes was used to identify T cell phenotypes and characterize the T cell repertoire.
Results. A conspicuous B and T cell infiltrate, primarily
clustered in perivascular spaces, was present in the microenvironment of most tumors examined. Characterization
of 294 tumor-infiltrating B cells revealed clear evidence of
antigen experience, in that the cardinal features of an
antigen-driven B cell response were present. Meningiomas
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harbored populations of antigen-experienced CD4+ and
CD8+ memory/effector T cells, regulatory T cells, and T
cells expressing the immune checkpoint molecules PD-1
and Tim-3, indicative of exhaustion. All of these phenotypes were considerably enriched relative to their frequency
in the circulation. The T cell repertoire in the tumor microenvironment included populations that were not reflected in
paired peripheral blood.
Conclusion. The tumor microenvironment of meningiomas often includes postgerminal center B cell populations.
These tumors invariably include a selected, antigen-experienced, effector T cell population enriched by those that
express markers of an exhausted phenotype.
Keywords: B cell, meningioma, T cell, tumor-infiltrating
lymphocytes.

M

eningiomas are brain tumors that arise from the
meninges surrounding the brain and spinal cord
and are among the most common adult neoplasms of the CNS.1 Although 80% of meningiomas are
slow-growing nonmalignant World Health Organization
(WHO) grade I tumors,2 they may still cause harm via
mass effect on neighboring structures. Favorable outcomes
for those WHO grade I tumors can often be achieved by
complete surgical resection. However, the atypical meningiomas, WHO grades II and III, can have more devastating
effects.
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Despite optimal management that includes surgical resection and radiation treatment, patients with grade II and
grade III tumors have 5-year survival rates of 78.5% and
44%, respectively, and corresponding 10-year survival
rates of 53.3% and 14.2%.3 Unfortunately, there is no
consensus for treatment strategies, and after several surgeries, treatment options are often limited. Thus, treatment strategies beyond radiation and surgery for these
patients are needed.4,5 One such strategy that is being explored in other primary brain tumors, such as gliomas, is
immunotherapy.6,7 Currently, our understanding of the
relationship between meningiomas and the immune
system is limited. By further exploring these interactions,
we aim to determine whether immunotherapeutic strategies could be used to target meningiomas.
Several studies in non-CNS tumors, such as lung
cancer, melanoma, ovarian cancer, and colon cancer, indicate that the presence of lymphocytes can be a critical
determinant of clinical prognosis.7 – 11 Furthermore, it
has been suggested that the types and distribution patterns
of these infiltrating lymphocytes can be more powerful
prognostic indicators than the previously used pathological criteria for tumor staging12 or oncogene expression.13
For example, a high tumor infiltrating CD8+/regulatory
T cell (Treg) ratio is often correlated with long-term survival.14 However, high levels of T cell response and antibody production can also be present in progressively
growing tumors, indicating that an immune response
does not necessarily result in immune protection.15 The
interaction between tumors and the immune system is
complex, and its outcome cannot be predicted from the
size of the infiltrate alone.
Immune cell infiltrates of meningiomas can include
variable numbers of T cells, B cells, plasma cells, and macrophages.16 – 20 Although the presence of immune cells in
meningiomas has been well delineated at a descriptive
level, many of the characteristics of these cells remain
unknown. Understanding whether such cells demonstrate
antigen experience, have developed into activated effector
cells, or display exhausted phenotypes is one of the first
steps toward understanding their role in tumor biology.
In the present work, we began to determine the role of
the immune cells that populate the tumor parenchyma
in meningiomas.

Materials and Methods

Table 1. Meningioma specimen demographics and mean TIL
counts
Tumor
ID

Grade
(WHO)

T Cells
(n)

3104

I

3

0

0.1

3113
3115

I
I

1.7
9

0.2
0.2

1.3
0

3125

I

8.4

0.2

0

3129
103111

I
I

0.1
0.1

2.3
0

0
0

2739

I

2.3

0.1

0

4217
001

I
I

3.2
3.4

0
1.8

0
1.2

002

I

1.7

0.3

0.6

004
025

I
I

9.2
2.4

1.4
4.2

0.2
0

032

I

1

0.3

0.67

033
034

I
I

0.3
0.3

0
0

0.3
0

027

I

5.1

0.3

0

029
2111

II
II

1.4
2.2

0.2
0

0
0

3106

II

1.1

0

0

3123
3152

II
II

2.4
4.2

0.2
0

0
0

3118

II

9.7

0.3

0

1343
1408

II
II

2.9
2.1

0
0.2

0
0

15016

II

5.9

0.1

0

2628
3097

III
III

3
0.6

0.2
0

0
0

3119

III

2.7

0

0.1

B Cells
(n )

Plasma Cells
(n )

compound immediately following surgical removal.
Many of the specimens that were large enough were also
dissected so that segments could be fixed in paraformaldehyde and embedded in paraffin. Sections from several
fresh specimens were reserved for flow cytometry-based
analysis. Fluorescence-activated cell sorted naı̈ve and
antigen-experienced B cells from normal healthy subjects
were used as controls. Institutional review boards at each
facility approved this study, and informed consent was
obtained from all subjects when required.

Clinical Specimens
Meningioma specimens were obtained from 28 patients
undergoing neurosurgical craniotomies for clinical indications unrelated to the current work. The sources of
tissue included Columbia University Medical Center,
Massachusetts General Hospital Cancer Center Tumor
Bank, and Yale School of Medicine. For meningiomas
025, 027, 029, 032, 033, and 034, peripheral blood
samples were obtained from the same patients at the
time of the surgery. The clinical demographics are summarized in Table 1. Sections from all of the specimens
were snap-frozen in optimal cutting temperature (OCT)
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Immunohistochemistry
Immunohistochemistry was performed on either
paraformaldehyde-fixed paraffin-embedded tissues or
OCT-embedded frozen tissues as previously described.21
Murine monoclonal anti-human CD20 (Clone L26, Dako
Cytomation) was used at a dilution of 1:250, anti-human
CD3 (Clone F7.2.38, Dako Cytomation) at 1:50, and antihuman CD138 (Clone MI15, Dako Cytomation) at 1:50.
Primary antibodies were applied for 1 h at room temperature. Slides were washed in Tris-HCl (50 mM, pH 7.4)
and incubated with anti-mouse secondary antibodies for
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1 h at room temperature. After further washing, the slides
were developed using diaminobenzidine chromogen and
counterstained with hematoxylin. Tumor-infiltrating lymphocytes (TILs) were enumerated under 400X magnification within 9 fields.

regions, which are 360 bp in length.26 Thus, we considered variants to be present when at least 2 bases were different. Statistical analysis of the sequencing data was
performed with the x2 test and Student’s t-test using
GraphPad Prism v6.0 software.

Immunoglobulin Variable Region Cloning

Quantification of Antigen-Driven Selection Strength

Immunoglobulin (Ig) variable region of heavy chain (VH)
libraries were constructed from frozen tumor specimens
(8 mm thickness) and from defined control subsets that included fluorescence-activated cell sorted naı̈ve (CD19+
CD272) and antigen-experienced (CD19 + CD27+) B
cells derived from the peripheral blood mononuclear
cells (PBMCs) of normal healthy subjects. Total mRNA
was extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. From the total
RNA, cDNA was synthesized and human Ig variable
region genes were amplified according to the protocol described by Wang and Stollar,22 with minor modifications
described by our group.21

After using IMGT/V-Quest to determine the germline
genes and the junction regions for each sequence, we
divided the sequences into clones. For meningioma 004
(95 sequences from serial sections), we were left with 1
clone of 6 sequences, 5 of size 4, 3 of size 3, and 4 of size
2. The rest were mono sequence clones. After the sequences
were divided into clones and a germline was assigned for
each clone, we used BASELINe27 in a focused binomial
test formulation28,29 to quantify the strength of antigendriven selection acting on the sequenced B cells. Due to uncertainty in the germline assignment of the D segment and
surrounding N and P additions,30 we used only mutations
in the V and J regions for the selection analysis.

Immunoglobulin VH Sequence Analysis

Immunophenotyping and T Cell Receptor Variable b
Repertoire Analysis by Flow Cytometry

The Ig VH sequences were analyzed using the
ImmunoGeneTics/V-Query and Standardization (IMGT/
V-Quest) tool (www.imgt.org)23 to assess isotype distribution, somatic hypermutation, and clonal expansion. The
first 10 primer encoded codons of framework region 1
(FR1) were excluded from this analysis. Allelic polymorphism was not considered in the assessment, because the Ig
variable gene alleles have very few such nucleotide substitutions,24 and the IMGT database includes various alleles for
alignment. Chimeric molecules arising from PCR amplification artifacts were not included in any analyses.25 The variable region cloning procedure also captures the 5′ end of the
Ig constant region, allowing the Ig isotype and thereby extent
of isotype switching to be determined. By aligning each sequence to the most homologous germline segments (V, D,
and J), the nucleotide mutations and amino acid replacements were counted. Clonal expansion and intraclonal
variants were determined as previously described.21
Clonal Expansion and Intraclonal Variation
Clones were identified through the invariably unique sequences of their third complementarity determining
region (CDR3). Identical sequences from nonconsecutive
tissue sections defined clonal expansion, whereas identical sequences within one tissue section were considered
to be the product of PCR amplification rather than expanded clones, as the two cannot be reliably distinguished. This highlights the need for the preparation of
distinct tissue libraries to properly evaluate clonal expansion. If 2 or more sequences had an identical CDR3 and
differed by at least 2 somatic mutations or at least 1
amino acid replacement in the VH region, they were considered to be derived from clonally related B cells, which
we termed clonal variants. The PCR enzyme used here introduces ,0.6 base changes into the amplified variable

Fresh single-cell suspensions from meningiomas were obtained by Percoll gradient centrifugation after mechanical
dispersion through nylon mesh cell strainers in Roswell
Park Memorial Institute media. Matched fresh PBMCs
were isolated by Ficoll-Hypaque gradient centrifugation.
For immunophenotyping analysis, flow cytometric analysis
was performed with the following anti-human surface and
intracellular antibodies: anti-CD4-V450 (Clone RPA-T4,
BD Bioscience), anti-CD8-V500 (Clone RPA-T8, BD
Bioscience), anti-Tim-3-PE (Clone F38-2E2, BioLegend),
anti-PD-1-PerCp-Cy5.5 (Clone EH12.1, BD Bioscience),
anti-CD45RA-APC (Clone HI100, BD Bioscience),
anti-CD45RO-APC-H7 (Clone UCHL1, BD Bioscience),
anti-CD25-Alexa700 (Clone BC96, BioLegend), and
anti-Foxp3-FITC (Clone PCH101, eBioScience). The T
cell receptor variable b domain (TCR Vb) repertoire in
tumor-infiltrating T cells (TIL-Ts) and whole blood was determined using the TCR Vb repertoire kit (IOTest Beta
Mark, Beckman Coulter) according to the manufacturer’s
protocol. Cells were stained simultaneously with antiCD3-APC (Clone UCHT1, BD Bioscience), anti-CD4-PECy7 (Clone SK3, BD Bioscience), anti-CD8-PerCP-Cy5.5
(Clone SK1, BioLegend), and 1 of 8 sets of antibody directed
against 3 distinct TCR Vb families. In this manner, TCR
usage from a total of 24 distinct Vb families (about 70%
coverage of normal human TCR Vb repertoire) was detected. All flow cytometric analyses were conducted on a LSR
Fortessa instrument (BD Bioscience), and FlowJo 9.4.11
software was used for analysis. To analyze differences in
Vb family usage, we calculated P-values using Pearson’s
x2 test to determine whether the observed TIL-T Vb
family frequency matched that expected from paired
whole blood, controlling for tube and total count
number. The Bonferroni correction was applied to
control for family-wise error rate.
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Results
Immunohistochemistry of Tumor-Infiltrating
Lymphocytes
All meningioma specimens were first examined for the
presence of an immune cell infiltrate using immunohistochemical markers for B cells (CD20+; Fig. 1A), plasma
cells (CD138+; Fig. 1B), and T cells (CD3+; Fig. 1C –
E). The frequency of cells was determined from the immunohistochemistry slides. Considerable variation among
the specimens was observed. B cells were found in 17/
28 (61%) of the tumors (Table 1). The density of the B
cell infiltrate was sparse in most specimens (Fig. 1A and
F). However, several had a more defined and conspicuous
infiltrate with clustering in the perivascular space.

Antibody-producing plasma cells were observed in 8/28
(28.5%) of the tumors (Table 1). The plasma cell
density was very sparse, often more diffuse than that of
B cells and present in fewer specimens (Fig. 1B and F). T
cells were seen in all 28 specimens, and their density was
greater than that of B cells (Fig. 1A– C and Table 1). T
cells often assembled in clusters in the perivascular
space (Fig. 1D and E) but were occasionally seen in the
tumor parenchyma in the absence of such clusters. To
determine how the immune cell infiltrate was distributed
throughout the entire tumor, one specimen with a robust
infiltrate of both B and T cells (004) was serial sectioned
along its z-axis to build a 3-dimensional reconstruction.
The density, distribution patterns, and phenotype of the
TILs were homogeneous throughout the entire tumor, indicating that no particular region provided a preferential

Fig. 1. Meningiomas harbor B, plasma, and T cell infiltrates within the tumor microenvironment. Immunohistochemistry demonstrated the
presence of CD20+ B cells (A), CD138+ antibody-secreting plasma cells (B), and CD3+ T cells (C). T cells often assembled in clusters
(arrow) in perivascular spaces (arrow head) (D and E). The images shown are representative of the specimens that had a visible infiltrate
under a 100X (A– C), 200X (D), and 400X (E) field. The inset is a magnification of the arrow-indicated site. The mean cell counts (within 9
fields per specimen under a 400X field) included all the specimens examined (F). Error bars indicate SEM.
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environment for the infiltrate. We then compared the
WHO grade of all 28 specimens with characteristics of
the infiltrate. Neither the frequency nor the type of cells
in the infiltrate correlated with tumor grade (not shown).

Molecular Characterization of Tumor-Infiltrating B Cell
Immunoglobulin Variable Regions
Having identified tumor-infiltrating B cells (TIL-Bs) in
most of the meningiomas we examined, we next constructed Ig VH libraries from the snap-frozen and serially
sectioned meningioma specimens to assess whether the
TIL-Bs had the characteristic features of an antigendriven response. This analysis was based on the Ig VH,
as its sequence complexity is significantly greater than
that observed in the light chain variable region. Isotype
switching, somatic mutation and amino acid replacement, and clonal expansion with intraclonal variation
provide clear evidence of an antigen-driven B cell response; thus, each of these characteristics was assessed.
B cells derived from nontumor sources were compared
with those derived from the meningiomas. In TIL-Bs,
there was abundant somatic mutation. On average, each
Ig VH of 400 nucleotides had a mean of 19 nucleotide mutations (relative to the germline allele), resulting in 11 amino
acid substitutions in TIL-Bs. There were even more nucleotide mutations in TIL-Bs than in antigen-experienced B cells
from healthy subjects (mean ¼ 15 nucleotide mutations)
(P ¼ .0138, Student’s t-test; Fig. 2A). The amino acid mutation values (mean ¼ 9 amino acid substitutions) were consistent with those of sorted antigen-experienced B cells (not
significant, Student’s t-test; Fig. 2B), while sorted naı̈ve B
cells showed few somatic mutations (,1 on average), as expected (P , .0001, Student’s t-test; Fig. 2A and B). No VH
gene was amplified from the control reactions that did not
contain RNA. No sequence overlap between different
tumor specimens was found. These results indicate
that no contamination or cross-contamination between
tumors occurred. Our immunohistochemistry-based
study indicated that several tumors did not harbor B
cells, but the molecular analysis confirmed their presence
in the same specimens. This discrepancy is likely due to the
lower sensitivity of the immunohistochemistry performed
with frozen specimens.
Meningioma 004 provided a representative example of
the characteristics of TIL-Bs in meningiomas. Ig VH libraries were constructed from 3 nonconsecutive sections.
Interestingly, we found clonally related TIL-Bs across
these distinct sections, indicating either that clonal expansion and migration occurred within the tumor or that these
clones evolved in a lymph node and then migrated to multiple regions within the tumor. Clonal expansion and intraclonal variation were typical among the B cells that
infiltrated the meningioma microenvironment. Among a
total of 294 sequenced TIL-Bs from 22 meningioma specimens, 46% were members of B cell clones, and the remaining 54% were unrelated to one another. On average, each
meningioma that we examined contained 3 B cell clones
(families) and 6 B cells that were members of clones, of
which 5 were clonal variants. Overall, among the clonally

expanded TIL-Bs, 80% could be identified as variants,
based on their distinct somatic mutation patterns relative
to their clonal family members. The frequency of a specific
B cell clone in the peripheral blood of normal individuals is
about 1/20 000;31 this indicates that the B cells we examined from the tumors were not derived from blood.
Furthermore, we observed no clonal expansion within
the sorted naı̈ve or antigen-experienced B cell populations
we studied (P , .0001, x2 test; Fig. 2C and D).
Given that naı̈ve B cells are defined by their expression
of IgM, we examined the isotype distribution of the
TIL-Bs and sorted antigen-experienced B cells. As expected, sorted antigen-experienced B cells had largely undergone class switching to the IgG isotype and were thus
not different from those derived from the tumor (not significant, x2 test; Fig. 2E), suggesting that the TIL-Bs were
also antigen experienced.
Figure 3A and B show more detailed analyses of 2 IgG
sequences that demonstrate the clonal expansion and
intraclonal diversity that were typical in these TIL-B populations. The two TIL-Bs (lj2 and 10/11 2 B) were both
detected in meningioma 004. Both silent and replacement
mutations were found throughout the variable regions,
including CDR3, compared with the germline VH allele.
The two TIL-Bs shared the same mutation pattern in
FR1, CDR1, FR2, and CDR2. The FR3 region of lj2 contained 1 additional amino acid substitution. Interestingly,
at one locus in the CDR3 region, lj2 contained 2 point mutations (from agt to aac), resulting in an amino acid substitution (from S to N), while 10/11 2 B contained 1 point
mutation (from agt to agc), without an amino acid substitution. This overlapping mutation pattern demonstrates
that these B cells are the progeny of the same parent cell,
which indicates that a process of antigen-driven maturation took place, either within the meningioma environment or in a lymph node.
To further confirm that the TIL-Bs were antigen
driven, we employed an algorithm (BASELINe) that detected selection by analyzing mutation patterns in experimentally derived Ig sequences. Using BASELINe, we
observed negative selection in the framework regions
and slightly positive/neutral selection in the complementary determining regions (Fig. 4). The difference between
the selection estimates in the different regions was highly
significant (P ¼ .0036), in agreement with normal
antigen-specific B cells. Collectively, these results indicate
that TIL-Bs had undergone activation, Ig class switching,
somatic hypermutation, and clonal expansion, all of
which are hallmarks of antigen exposure.

Phenotypes and Frequencies of Tumor-Infiltrating T Cells
Having demonstrated that most TIL-Bs were antigen experienced, we asked whether tumor-infiltrating T cells
TIL-Ts also exhibited the characteristics of an antigendriven response. We used flow cytometry to further
assess the phenotypes and frequencies of TIL-Ts and compared those to PBMCs from the same patients. First, we
investigated the distribution of CD4+ and CD8+ cells
within the T cell populations of tumor and matched
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Fig. 2. The immunoglobulin repertoire of TIL-Bs and peripheral B cells. TIL-Bs (294 sequences), fluorescence-activated cell sorted naı̈ve B cells (34
sequences), and fluorescence-activated cell sorted antigen (Ag)-experienced B cells (45) were analyzed for evidence of antigen-driven
characteristics. (A and B) Extent of somatic mutation and amino acid (AA) replacement (average number), NT: nucleotide. Error bars indicate
SEM; (C) clonal expansion. Black columns represent the percentage of clonally expanded sequences, and white columns represent
percentages of the other analyzed sequences that were not clonally expanded sequences (singles); (D) intraclonal variants. Black columns
represent the percentage of B cells within the expanded clones that were variants (having undergone somatic mutation), and white columns
represent the percentage of B cells within the expanded clones that were not variants (individual B cells); (E) heavy chain isotype distribution
(%) in fluorescence-activated cell sorted antigen-experienced B cells and TIL-Bs. Statistical differences are shown when significant.

peripheral blood. Then, naı̈ve and antigen-experienced
subsets were examined based on the expression of
CD45RA and CD45RO. We found that there were
more CD8+ T cells than CD4+ T cells in the meningiomas, while this ratio was reversed in matched PBMCs
(Fig. 5A). That is, TIL-Ts had a lower frequency of
CD4+ cells and a higher frequency of CD8+ cells compared with PBMCs, but the differences were not significant (Student’s t-test; Fig. 5A). Among TIL-Ts
expressing CD4 or CD8, there was a significantly higher
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percentage of cells with a memory/effector phenotype
(CD45RO+CD45RA2) and a significantly lower frequency of naı̈ve cells (CD45RO2CD45RA+) compared
with CD4+ and CD8+ PBMCs (P , .05, Student’s t-test;
Fig. 5B and C). The T cell infiltrate was also enriched in
CD4+ CD25+ Foxp3+ Tregs relative to matched
PBMCs (P , .05, Student’s t-test; Fig. 5B). We next examined the negative regulatory or immune checkpoint
molecules programmed death-1 (PD-1) and T cell Ig and
mucin protein-3 (Tim-3) expression on TIL-Ts.32 These

Fang et al.: Adaptive immune response in meningiomas

Fig. 3. Clonal expansion and intraclonal diversity of a B cell clone isolated from a meningioma. (A) Alignment of CDR3 protein sequences, as well
as V-D-J gene segment use, of clonally related TIL-Bs. Amino acid differences are italicized and in bold compared with the CDR3 region encoded
by the germline allele. (B) Variable gene segments were aligned at the nucleotide level for 2 clonally related TIL-Bs. Solid vertical lines represent
coding mutations that resulted in amino acid replacement, and dashed lines represent silent mutations, compared with the most homologous
germline segment.

Fig. 4. Quantification of antigen-driven selection strength using
BASELINe. The top half of the plot shows the estimated selection
strength in the complementary determining regions (CDR), while
the bottom part provides an estimate for the framework regions
(FWR). Negative sigma values indicate negative selection, while
positive values indicate positive selection. In the meningioma 004
sequences shown here, we observed negative selection in the
framework regions and slightly positive/neutral selection in the
complementary determining regions. The difference between the
selection estimates in the different regions is highly significant (P ¼
.0036), in agreement with normal antigen-specific B cells.

molecules, often observed on TIL-Ts, are associated with
an exhausted phenotype.33 Compared with PBMCs in

both CD4+ and CD8+ TIL-Ts, we found a significant increase in the expression of PD-1 (P , .05, Student’s t-test)
and a trend of increased expression of Tim-3, but no significance difference (Student’s t-test) (Fig. 5D). These collective changes in the TIL-T populations suggested that
they experienced antigen-driven activation, which was
consistent with our findings for TIL-Bs.
We used an additional, complementary approach to
determine whether the tumor microenvironment included an immune repertoire that differed from that in the periphery. The T cell repertoire, assessed by TCR Vb usage,
from both the TILs and periphery was determined. The
CD4+ and CD8+ subsets were examined separately. In
agreement with other reports, the T cell repertoire
varied among individual patients,34 so we focused on
comparing the repertoire of TIL-Ts and PBMCs from
the same patient. The TCR Vb repertoire expressed by
CD4+ TIL-Ts generally resembled the diverse TCR Vb
profile expressed by CD4+ T cells in matched peripheral
blood (Supplementary data). The usage of some Vb families in the CD4+ subset was statistically different, but the
overall profile was quite similar. The TCR repertoire of
CD8+ T cells in the TILs was, however, quite different
from that in matched peripheral blood. Relative to
matched peripheral blood, a number of families were considerably overrepresented in the TIL-Ts, while some were
less apparent or not represented at all (Fig. 6 and
Supplementary data). The CD8+ TCR Vb repertoire
from meningioma 032 is shown as a representative case
and highlights these differences well (Fig. 6). Here, 3 families (Vb3, 20, and 21.3) were preferentially expressed
within the TILs, such that they represented more than
half of the TCR Vb repertoire. However, in the paired periphery, these families accounted for only 8% of the

NEURO-ONCOLOGY

†

NOVEMBER 2013

1485

Fang et al.: Adaptive immune response in meningiomas

Fig. 5. Flow cytometric analysis of TIL-Ts and matched PBMCs. TIL-Ts (025, 027, 029) and matched PBMCs were first gated by CD4+ and CD8+
T cell subsets. Then the surface markers CD45RA, CD45RO, PD-1, Tim-3, CD25, and the intracellular marker Foxp3 were used to demarcate
particular T cell subsets. (A) Frequency of CD4+ and CD8+ T cell subsets. (B) Frequency of naı̈ve (CD45RA+CD45RO-), antigen
(Ag)-experienced memory/effector (CD45RA2CD45RO+) and Treg (CD25+Foxp3+) populations within CD4+ T cell subsets. (C)
Frequency of naı̈ve (CD45RA+CD45RO2), antigen-experienced memory/effector (CD45RA2CD45RO+) populations within CD8+ T cell
subsets. (D) Frequency of T cells displaying an exhausted phenotype (PD-1+ and Tim-3+) within the CD4+ and CD8+ T cell subsets. Error
bars represent SEMs. Statistical differences are shown when significant.

overexpressed in the peripheral blood (6.3%) of tumor
032 but was absent from the TILs (P , .05, x2 test; Fig. 6).

Discussion

Fig. 6. TCR Vb repertoire of a meningioma T cell infiltrate and paired
blood. An informative example of the expansions and omissions
within the tumor T cell repertoire compared with those of the
peripheral blood is shown. In this example, the TCR Vb usage
within the CD3+CD8+ T cell population from meningioma 032
and matched peripheral blood are compared. Statistical differences
are shown when significant.

repertoire. Particular families were substantially diminished in the TILs. For example, the Vb2 family was
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TILs are harbored by many solid tumors, including melanoma, colon cancers, breast cancers, lung cancer, intracranial germinomas, and meningiomas.21,35 – 37 The precise
nature of the role TILs play remains to be thoroughly described. TILs appear to have a tumoricidal capacity, as
their adoptive transfer participates in the resolution of established cancer in murine tumor models38 and successful
regression of human neoplasms.39 However, inflammation
can also play the opposite role by promoting tumor progression.40 This can be achieved by selecting for tumor
cells that are capable of survival in the context of an
immune response (immunoediting)41 or by contributing
to conditions within the tumor microenvironment that facilitates tumor outgrowth.15,42
Although TILs have been intensely studied in a number
of tumors, fewer studies have been focused on meningiomas. This may be due to the fact that meningiomas are
often considered benign neoplasms and are more easily
treated than gliomas and medulloblastomas, resulting in
favorable outcomes. However, their recurrence rates
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vary 7% – 25% for WHO grade I, 29%– 52% for WHO
grade II, and 50% –94% for WHO grade III,43 the latter
being associated with a 1.5-year median survival.44
Moreover, benign meningiomas can still cause significant
problems due to mass effects and limited surgical access
inherent to their proximity to the skull base. Given that
immunotherapy is emerging as a conceivable treatment
approach and that the TILs of meningiomas have not
been thoroughly characterized, a more complete understanding of the TIL repertoire is needed. Accordingly,
we focused our study on further defining the phenotypes
of the immune cell infiltrate in a series of meningiomas.
To begin, immunohistochemistry was used to identify
the presence of B and T cells within meningioma tissues,
and then the number of TIL subsets was counted to quantify the infiltrate. The organization of the infiltrate along
with its distribution throughout the tumor was also assessed. We undertook a molecular characterization of
the B cell antigen receptor repertoire to test whether
these cells had previously encountered antigen. Flow cytometry was performed to determine which T cell
subsets were present and whether they displayed phenotypic markers associated with tumor evasion of cellular
immunity. Finally, a flow cytometry-based TCR Vb
chain usage assay allowed us to determine the profile of
the T cell repertoire in these tumors. Comparing the
results found in the tumor with those from matched
blood considerably strengthened all of the flow cytometry-based studies; we were able to observe enrichment of
cell types in the tumor that would not have been appreciated by studying the tumor-derived cells alone.
A discernible T and B cell infiltrate was present in the
microenvironment of most meningiomas examined;
these tumors often harbored B cells and invariably included a T cell infiltrate. However, heterogeneity between
tumors, both in terms of cell type and frequency, was a
consistent finding. B cell Ig variable regions revealed
clear evidence of antigen experience. The CD8+ T cell
frequency was higher than CD4+, a ratio that was reversed in the periphery of the subjects we studied. Tregs,
capable of suppressing immune responses, were enriched
in the tumor. Although the T cells were antigen experienced memory/effector cells and were enriched relative
to the blood, many displayed a phenotype associated
with exhaustion (PD-1+, Tim-3+), indicating that they
may not be capable of mounting an effective response.
The shape of the T cell repertoire (identified by Vb
usage) in the CD4+ and CD8+ compartments was different than that found in the peripheral blood of the same individual, suggesting that the T cells migrating and residing
in the tumor were selected by a specific antigen or antigens
expressed in the tumor.
Little is known about TIL-Bs, which often co-localize
with T cells, enhancing T cell responses by producing antibodies, stimulatory cytokines, and chemokines and
serving as local antigen presenting cells (APCs).35
Interestingly, the presence of B cells in tumors is thought
to have a paradoxical effect. In tumor immunity, activated B cells may play a beneficial role in the chronic immune
process by expressing the costimulatory activities needed
to activate naı̈ve CD4+ T cells and by acting as APCs

capable of promoting immune responses.45 Conversely,
resting B cells can inhibit T cell responses via a mechanism
dependent on major histocompatibility complex class
II.46 B cells need to encounter their specific antigen to activate their function. The presence of substantial B cell
numbers dispersing throughout the microenvironment
of many meningiomas suggests a role for an antigendriven, antibody-mediated immune response within the
meningioma tissue or nonspecific lymphocyte recruitment by inflammatory and chemotactic cytokines.
The vast majority of B cells that were present in the
tumors we studied were antigen experienced, indicating
that they had migrated to the tumor after maturing in a germinal center. Given that immunohistochemistry indicated
that the B cell family infiltrate included a small fraction of
plasma cells, we concluded that these were primarily
memory B cells. Infiltrates of clonally expanded memory
B cells have been observed in other solid tumors.47 These
B cells had switched from IgM to the IgG isotype. The
process of Ig isotype switching requires specific interactions between CD4+ T cells and B cells along with the expression of activation-induced deaminase. Ig isotype
switching is a codependent process involving the B cell receptor and CD40 and CD40L (ligand). CD40, expressed
on B cells, is a member of the tumor necrosis factor receptor
superfamily and is critical for B cell Ig isotype switching
and the formation of the germinal center. Binding to
CD40L expressed on activated T cells to CD40 on B cells
activates the isotype switching process. Thus, the role of
CD40 and CD40L is a crucial event in T cell priming and
ultimately Ig isotype switching.48 That IgG frequency
was significantly higher than IgM frequency suggests that
these B cells most likely undergo additional clonal expansion outside of the tumor microenvironment at a nearby
site where they can interact with antigen-specific T cells
and migrate to the tumor. It is possible that tumor antigens
could drive this process.
TIL-Bs could mediate their effects through the production of tumor-specific antibodies. To investigate this possibility, we looked for evidence of an antigen-driven
immune response within the tumor tissue by examining
the nature of the B cell infiltrate in meningiomas. The molecular features of the B cell antigen receptor expressed by
tumor-associated B cells were elucidated, thereby describing the characteristics of the B cell infiltrate. Although B
cells appear to represent the lowest frequency of the
immune cell infiltrates, they do not appear to be innocuous. Indeed, these are fully mature functional B cells.
Our phenotypic characterization of the intratumoral B
cell repertoire revealed that the resident B cells included
(i) expanded sets of clones, (ii) intraclonal variation,
(iii) Ig genes that had undergone isotype switching, and
(iv) somatic mutations within these genes. These are fundamental features of antigen-driven B cell maturation requiring T cell help and CD40-CD40L interaction. Although
mature, antigen-experienced B cells were present, we did
not observe extranodal lymphoid-like follicles that have
been shown to populate a number of other tumor
types.21,49,50 These structures, present in normal lymph
nodes, are the site of antigen-driven B cell affinity maturation. That such structures are absent from meningiomas
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suggests that the experienced B cells present in the tumor parenchyma mature elsewhere and then migrate to the tumor.
The degree of heterogeneity among the TILs in meningiomas has not been addressed. Indeed, it is possible that
there could be different microenvironments. For example,
it would be reasonable to consider that there could be
zones of augmented TILs, specifically in the perivascular
space and near the arachnoid cap. We investigated the
TILs throughout the z-axis of one specimen to further
investigate the possibility of heterogeneity as a cause.
Immunohistochemistry did not reveal such heterogeneity,
as the infiltrate was rather consistently distributed. B cell
repertoires of this tumor were prepared from 3 distinct
regions that were separated by at least 0.25 cm. The B
cell repertoires were surprisingly consistent and did not
suggest the presence of different microenvironments
located throughout the tissue. Interestingly, B cells
derived from the same clone (parent) were found in each
distinct region. This suggests that an antigen in the
tumor parenchyma recognized by this expanded B cell
clone, may be the target of these cells. Although such experiments were beyond the scope of the present study,
there are established approaches to investigate this possibility. These include expression of recombinant Ig51,52
and ex vivo B cell expansion53 from a dominant, tumorassociated clone. The IgG derived from these approaches
could then be screened on meningioma-derived antigens.
Meningioma-derived T cells have been studied more
than B cells have been. In agreement with other studies,
we found T cells to be more frequent than B cells, both in
terms of the magnitude of the infiltrate and the number
of tumors including such cells. T cells of the CD8+
subtype within a number of solid tumors often outnumber
the CD4+ T cell population.54 This phenomenon is consistent with our findings in that we invariably observed more
CD8+ T cells in all 28 tumors studied. When examined for
the presence of effector functions, both subsets included an
enrichment of antigen-experienced memory/effector cells
relative to those circulating in the same patients. This approach wherein the tumor homogenate was compared
with the PBMCs of the same individual allowed us to be
certain that the analysis was not erroneously focused on
cells derived from the tumor vasculature but included TILs.
In addition to CD4+ and CD8+ T cells, Tregs were
present in the infiltrates. Tregs have been observed in a
number of solid tumors,55,56 and their presence, although
less frequent than that observed in glioblastomas, has
been reported in meningiomas.57 This T cell subset is responsible for suppressing the immune response and may
assist the tumor in evading the immune system by affecting the antigen-presenting process of dendritic cells,
directly contacting and lysing effector T cells, and secreting cytokines such as interleukin 10 and transforming
growth factor b.58 The infiltrates examined also included
T cells expressing Tim-3 and PD-1, indicative of T cell exhaustion. Such cells have been observed among the infiltrates of other solid tumors.59 Both the Tregs and
exhausted T cells were enriched in the tumor compared
with the periphery, indicative of preferential selection of
particular T cell clones in the tumor but not in the circulation. The presence of these 2 cell types implies that the
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T cell response in meningiomas contributes to an immunosuppressive environment.
We did not observe significant associations between the
characteristics of the TILs we identified and meningioma
WHO grades. Future studies comprising larger cohorts,
should evaluate whether such correlations exist. This is
particularly relevant given that meningioma subgroups
defined by several characteristics, including genetics and
anatomical location, have recently been reported.60
Indeed, whether characteristics of the TILs further define
these established subgroups will be valuable for prognosis,
treatment response, and selection of therapeutic options. It
is becoming clear that the immune composition of primary
tumors is an essential prognostic factor for tumor eradication and overall survival,61 both of which represent important consequences in clinical practice.
We must also continue to investigate how a tumor is
able to grow in an environment that includes a host
immune response. Does this occur because it is recognizable as normal tissue and thus tolerated by immune
cells, or because it evades immunosurveillance? Future
immunotherapy, dependent on this understanding, may
be an effective adjunct to standard therapy, reversing immunologic tolerance in the tumor microenvironment. The
immune response is not entirely effective in eliminating
meningiomas. Given that these tumors include an infiltrate of antigen-experienced B and T cells, it is possible
that an equilibrium has been established between the
tumor and the immune system.62 This balance may
result in the slow growth that is characteristic of many meningiomas. More aggressive tumors may move past this
equilibrium into a phase of immune evasion allowing progression and metastasis. The collective data shown here
indicate that the microenvironment of meningiomas supports an active immune response that may be maintained
through the expression of specific antigens. This understanding of the microenvironment, along with the future
identification of such tumor antigens, provides the potential for the design, development, and clinical application
of immunotherapy that one day may include directed
cancer vaccines.
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